Aim: Aim of this study was to evaluate the effect of anakinra (ANK) addition to remdesivir (RDV) on all-cause 28-day mortality in patients hospitalized with COVID-19. Patients & methods: ANK was administered intravenously at a dose of 5 mg/kg every 12 h in patients with severe respiratory failure and pronounced inflammatory status. 58 patients were treated with RDV + ANK, 219 patients with RDV. Results: The estimate of mortality at 28 days was 17.2% in the RDV + ANK group and 21.4% in the RDV group. Median time to death was 14 days in the RDV + ANK group and 19 in the RDV group. Conclusion: Despite severe respiratory failure and pronounced inflammatory status, patients who received RDV + ANK had similar mortality compared with patients who received RDV.
Real-life use of high-dose anakinra in patients with COVID-19 treated with remdesivir / Monardo, R.; Mastrangelo, A.; Galli, L.; Tomelleri, A.; Spagnuolo, V.; Oltolini, C.; Ponta, G.; Campochiaro, C.; Cavalli, G.; Dagna, L.; Ciceri, F.; Cinque, P.; Scarpellini, P.; Castagna, A.; Ripa, M.. - In: FUTURE VIROLOGY. - ISSN 1746-0794. - 19:1(2024), pp. 11-17. [10.2217/fvl-2023-0132]
Real-life use of high-dose anakinra in patients with COVID-19 treated with remdesivir
Monardo R.;Mastrangelo A.;Tomelleri A.;Spagnuolo V.;Ponta G.;Campochiaro C.;Cavalli G.;Dagna L.;Ciceri F.;Castagna A.;Ripa M.
2024-01-01
Abstract
Aim: Aim of this study was to evaluate the effect of anakinra (ANK) addition to remdesivir (RDV) on all-cause 28-day mortality in patients hospitalized with COVID-19. Patients & methods: ANK was administered intravenously at a dose of 5 mg/kg every 12 h in patients with severe respiratory failure and pronounced inflammatory status. 58 patients were treated with RDV + ANK, 219 patients with RDV. Results: The estimate of mortality at 28 days was 17.2% in the RDV + ANK group and 21.4% in the RDV group. Median time to death was 14 days in the RDV + ANK group and 19 in the RDV group. Conclusion: Despite severe respiratory failure and pronounced inflammatory status, patients who received RDV + ANK had similar mortality compared with patients who received RDV.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
